International Ceftriaxone Sodium Hydrate Injection 1 Gram

Adult administration

For adults and children over 12 years old, administer 1-2 g (potency) of ceftriaxone once daily via intravenous or intramuscular injection. For infections by pathogens with moderate susceptibility or in severe disease, the dose can be increased to 4 g (potency) once daily. For treatment of meningitis, adults, including elderly patients, should follow the adult dosage without modification. For the treatment of gonorrhea, a single intramuscular injection of 250 mg (potency) is advised.

Child administration

For newborns (up to 14 days old), 20-50 mg (potency) per kg of body weight is administered once daily, not exceeding 50 mg (potency). For infants and children (15 days to 12 years old), 20-

This drug should not be mixed or administered simultaneously with solutions containing calcium or other drugs. Particularly, it should not be administered to newborns younger than 28 days in conjunction with calcium-containing solutions, as it may be dangerous. Serious side effects have been reported in newborns or premature infants who received this drug with calcium solutions, leading to the formation of deposits in the lungs or kidneys. Patients with allergic reactions to this drug or hypersensitivity to cephalosporins or penicillin antibiotics should not use this product. This drug, which contains lidocaine, should not be given via intravenous injection. Newborns with jaundice or issues with bilirubin binding should not use this drug due to the risk of bilirubin encephalopathy. Patients with a history of drug allergies or allergic constitution and those with severe renal impairment should be administered this drug with caution. During administration, it is important to monitor liver function, kidney function, and blood tests regularly. Various side effects such as diarrhea, rash, increased liver enzymes, and reduced blood cell counts may occur; if any adverse symptoms are noted, immediate medical attention should be sought. If severe allergic reactions or symptoms of shock occur, administration must be stopped immediately and emergency treatment should be received. This drug should be used cautiously during pregnancy or breastfeeding based on the physician's judgment. Elderly patients or those with reduced kidney function need dosage adjustments and status monitoring. This drug may interact with other medications, so disclosure of current medications is essential. During administration, avoid mixing with calcium-containing solutions and do not mix with aminoglycoside antibiotics in the same syringe. Prepared solutions should be used as soon as possible, and it is recommended to use within 6 hours at room temperature or within 24 hours if refrigerated.

Serious side effects

Hives, severe swelling (edema), cold sweats, pallor, severe allergic reactions, severe rash with high fever, blisters, skin peeling, pain in oral/ocular mucosa, severe skin adverse reactions, shortness of breath or difficulty breathing, asthma attacks, respiratory problems with cough and fever, jaundice (yellowing of skin or eyes), profound lethargy, liver dysfunction (jaundice), sudden and severe headache, thunderclap headache

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• increased liver enzymes
• headache
• dizziness
• bronchospasm
• loose stools

Store this drug in a sealed container to prevent exposure to air, and it is advisable to keep it at room temperature away from direct sunlight. This will help maintain the efficacy of the drug for a longer period.

Appearance

(For domestic use) A vial filled with white to light yellow crystalline powder. (For export) A colorless, transparent vial containing white to light yellow powder.

Package unit

10 vials/box [(1 vial × 10)]